TapImmune’s new CEO shares the potential of cancer immunotherapies – Jacksonville Business Journal
Jacksonville Business Journal |
TapImmune's new CEO shares the potential of cancer immunotherapies
Jacksonville Business Journal TapImmune (Nasdaq: TPIV) develops cancer-fighting immunotherapies that target breast and ovarian cancers. Immunotherapies that combat cancer are hardly five-years-old, and much of the science behind them was learned in the last decade. Hoang, who … |
